Dr. Christopher B. Lock, MD
Neurology (Clinical Neurophysiology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 46
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 163
Licensed in California since 1994, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Neurophysiology Physician primary
CA license A53673 (first issued 1994; current) -
Neurology Physician
CA license A53673 (first issued 1994; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
- Stanford Health Care Tri-Valley Pleasanton, CA
- Peninsula Medical Center Burlingame, CA
- Memorial Medical Center Modesto, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 163
- Services billed
- 286
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 177 | 99 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 73 | 56 |
| New patient office or other outpatient visit, 60-74 minutes | 69 | 69 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Stanford, CA | 70 |
| Baclofen Other prescribers in Stanford, CA | 54 |
| Kesimpta Pen (ofatumumab) | 35 |
| Dalfampridine Er (dalfampridine) | 29 |
| Pregabalin Other prescribers in Stanford, CA | 25 |
| Levetiracetam Other prescribers in Stanford, CA | 18 |
| Oxcarbazepine Other prescribers in Stanford, CA | 16 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Stanford, CA | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 16 payments worth $12,341 in total to this clinician.
| Amgen Inc. | $12,315 |
|---|---|
| Biogen, Inc. | $25.80 |
| Compensation for services other than consulting (speaking, faculty) | $11,000 |
|---|---|
| Travel and Lodging | $1,163 |
| Food and Beverage | $178 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $550 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $550 |
| Amgen Inc. May 3, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA · in-kind | $345 |
| Amgen Inc. May 3, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SACRAMENTO, CA · in-kind | $345 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA | $179 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SACRAMENTO, CA | $179 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA | $49.00 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $550 |
| Amgen Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $550 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA | $179 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SACRAMENTO, CA | $179 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA | $49.00 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SACRAMENTO, CA | $49.00 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA | $8.00 |
| Amgen Inc. May 19, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SACRAMENTO, CA | $8.00 |
| Amgen Inc. May 3, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to Sacramento, CA · in-kind | $345 |
| Amgen Inc. May 3, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SACRAMENTO, CA · in-kind | $345 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $518,178 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
UCB SA · Active, not recruiting · NCT05063162 - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - First in human study RO7121932
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.